Institut De Recherches Internationales Servier

This study tests a new drug, vorasidenib, combined with a standard chemotherapy (temozolomide) for people with a specific type of brain tumor (glioma) that has an IDH1 or IDH2 mutation. The goal is to find the safest dose and see if the combination helps control the tumor. About …

This Phase 3 trial tests whether adding ivosidenib (a targeted pill) to standard azacitidine helps adults with a specific IDH1-mutated acute myeloid leukemia (AML) who cannot have intensive chemotherapy. About 146 participants receive either the combo or a placebo plus azacitidin…

This early-stage trial tests two new targeted drugs (AG-120 and AG-221) given alongside standard chemotherapy for people with a specific genetic form of acute myeloid leukemia (AML). The study includes about 153 adults with newly diagnosed AML that has an IDH1 or IDH2 mutation. T…

This early-phase trial is testing whether combining two drugs—vorasidenib and pembrolizumab—can help people with a specific type of brain tumor (IDH-1 mutant glioma) that has come back or is growing. About 60 participants will receive the drugs before and after surgery to remove …

This early-stage trial aimed to test a new drug called S095033 combined with the chemotherapy paclitaxel in people with advanced or metastatic esophageal squamous cell carcinoma. The goal was to check safety, tolerability, and signs of tumor shrinkage. However, the study was with…

This phase 3 study tests whether a combination of trifluridine/tipiracil (a chemotherapy pill) and bevacizumab (a targeted therapy) works better than the current standard of capecitabine plus bevacizumab for people with metastatic colorectal cancer who are not healthy enough for …